We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
GLOBETECH PUBLISHING LLC

Download Mobile App




RT Offers Hope for High-Risk Arrhythmia Patients

By MedImaging International staff writers
Posted on 09 Oct 2019
Print article
Image: According to a new study, RT can offer hope the VT patients who have exhausted other options (Photo courtesy of SPL).
Image: According to a new study, RT can offer hope the VT patients who have exhausted other options (Photo courtesy of SPL).
A single, high dose of radiation therapy (RT) can dramatically reduce episodes of ventricular tachycardia (VT) for more than two years, according to a new study.

Developed at the Washington University (WUSTL; St. Louis, MO, USA) School of Medicine, the noninvasive, outpatient procedure for treating VT is called EP-guided noninvasive cardiac radioablation (ENCORE). The novel therapy fuses electrocardiogram (ECG) and imaging data to pinpoint the scar tissue in the patient's heart responsible for the arrhythmias, and then targets it with a single dose of stereotactic body radiation therapy (SBRT). ENCORE requires no general anesthesia, and allows patients to go home immediately after treatment.

In a phase I/II prospective trial, 19 patients who had life-threatening VT were treated with a single fraction (25 Gy) of SBRT. ENCORE led to a 94% reduction in VT episodes in the first six months after SBRT, with longer-term follow-up data showing that the effect persisted in 78% of patients for more than two years; overall survival was 52% after the second year. Of the nine patients who died, six suffered from cardiac deaths (heart failure and VT recurrence) and three from non-cardiac deaths (accident, amiodarone toxicity, and pancreatic cancer). The study was presented at the 61st annual meeting of the American Society for Radiation Oncology (ASTRO), held during September 2019 in Chicago (IL, USA).

“Patients come to us as a last line of defense. They have few or no other options. Often, the primary reason we are treating them is because they were too sick to have more catheter ablation,” said lead author and study presenter Clifford Robinson, MD, an associate professor of radiation oncology and cardiology at WUSTL. “Given the relative novelty of this treatment approach, we are following our patients closely, conducting trials to gather more data and being careful not to make assumptions at this point.”

“An additional benefit to treatment was a reduction in the medications patients were taking, which resulted in fewer medication-related side effects and a higher quality of life,” concluded Dr. Robinson. “These patients were on heavy doses of medications, with side effects such as liver damage, lung damage, nausea, and thyroid problems. After they were treated, we could dramatically reduce their medications. We saw reduced VT, reduced medication and improved quality of life, at least in the intermediate term.”

In VT, the electrical signals in the heart’s lower chambers misfire, crippling the relaxation and refilling process and producing rapid arrhythmias. First line treatment for VT includes pharmaceuticals and an implantable cardioverter defibrillator (ICD). Patients with recurrent VT often also undergo catheter ablation, which requires general anesthesia, takes up to nine hours to perform, holds a 5% mortality risk, and has a 50% chance that it won't stop VT arrhythmias from recurring. If catheter ablation does not control the VT, patients are left with few options beyond a heart transplant.

Related Links:
Washington University

Gold Member
Solid State Kv/Dose Multi-Sensor
AGMS-DM+
New
Brachytherapy Planning System
Oncentra Brachy
New
Portable X-Ray Unit
AJEX240H
New
PACS Workstation
CHILI Web Viewer

Print article

Channels

Radiography

view channel
:	Image: The AI model could be a valuable adjunct to human radiologists in breast cancer diagnoses and risk prediction (Photo courtesy of 123RF)

AI Model Predicts 5-Year Breast Cancer Risk from Mammograms

Approximately 13% of U.S. women, or one in every eight, are predicted to develop invasive breast cancer over their lifetime, with 1 in 39 women (3%) succumbing to the illness, according to the American... Read more

General/Advanced Imaging

view channel
Image: The CIARTIC Move self-driving mobile C-arm has received FDA clearance (Photo courtesy of Siemens)

Self-Driving Mobile C-Arm Reduces Imaging Time during Surgery

Intraoperative imaging faces significant challenges due to staff shortages and the high demands placed on surgical teams in the operating room (OR). A common challenge during many OR procedures is the... Read more

Imaging IT

view channel
Image: The new Medical Imaging Suite makes healthcare imaging data more accessible, interoperable and useful (Photo courtesy of Google Cloud)

New Google Cloud Medical Imaging Suite Makes Imaging Healthcare Data More Accessible

Medical imaging is a critical tool used to diagnose patients, and there are billions of medical images scanned globally each year. Imaging data accounts for about 90% of all healthcare data1 and, until... Read more

Industry News

view channel
Image: Samsung Medison CEO Mr. Yongkwan Kim and Bracco Imaging CEO Dr. Fulvio Renoldi Bracco endorsed a MoU agreement (Photo courtesy of Bracco Group)

Samsung and Bracco Enter Into New Diagnostic Ultrasound Technology Agreement

Samsung Medison (Seoul, South Korea) and Bracco Imaging (Milan, Italy) have entered into a Memorandum of Understanding (MoU) agreement to pioneer a new area for diagnostic ultrasound devices and contrast agents.... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.